Wheeler Jonathan H.
Known title: DirectorCIK: 0001529427
Associated companies
Transaction History
| CCEL | ▲ Buy | Option Exercise | 7,500 | $56K | 9/17/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 5,300 | $41K | 9/17/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 5,300 | $42K | 9/17/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 7,500 | $15K | 9/13/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 7,500 | $15K | 9/13/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 7,500 | $18K | 9/13/2021 | View on chart |
| CCEL | ▲ Buy | Option Exercise | 7,500 | $23K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates
Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.
Cryo-Cell International (CCEL) Q3 Profit Beats Estimates. Cryo-Cell International reported third‑quarter 2026 results showing profit that exceeded analysts’ expectations while revenue remained essentially unchanged. Earnings per share rose to $0.16 from $0.09 a year earlier, and net sales were $7.82 million, a marginal dip from $7.83 million. The stronger earnings come as the stock trades near its 52‑week high and sits just above the 200‑day moving average.